Establishment of therapeutic strategy for pancreatic cancer by hypoxic PET

2018 Fiscal Year Final Research Report

• Project/Area Number: 15K09970
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Saitama Medical University
• Principal Investigator: Yamane Tomohiko 埼玉医科大学, 医学部, 准教授 (20526660)
• Co-Investigator(Kenkyū-buntansha): 久慈 一英 埼玉医科大学, 医学部, 教授 (90283142) ; 合川 公康 埼玉医科大学, 医学部, 准教授 (20438823) ; 良沢 昭銘 埼玉医科大学, 医学部, 教授 (60363123)
• Project Period (FY): 2015-04-01 – 2019-03-31
• Keywords: 低酸素 / 膵臓癌 / F-18 FMISO / PET/CT

Outline of Final Research Achievements

At first, we tried to establish a protocol of [18F]FMISO-PET / CT for pancreatic cancer patients and showed that it is appropriate to acquire PET/CT images 150 minutes after intravenous injection of 7.4MBq/kg [18F]FMISO.
Then, [18F]FMISO-PET/CT was performed for patients with pancreatic cancer scheduled for surgery. The following results were obtained: (1) [18F]FMISO uptake tended to be higher in patients who did not apply surgery, but no significant difference was found. (2) Cases with strong HIF-1α expression in surgical specimens tended to have high [18F]FMISO accumulation, but there was no significant difference. (3) The group of pancreatic cancer with high accumulation of [18F] FMISO have significantly shorter recurrence-free survival and overall survival than the group without.

Free Research Field

放射線医学・核医学

Academic Significance and Societal Importance of the Research Achievements

ポジトロン断層・コンピュータ断層複合撮影（PET/CT）を用いることで、腫瘍の代謝や機能情報を得ることができる。本研究は組織低酸素を評価できるとされる[18F]fluoromisonidazole (FMISO)と呼ばれる放射性医薬品を用い膵臓癌の低酸素を非侵襲的に評価し、これが予後に関連するか否かについて検討を行った。
手術が予定された膵臓癌の症例に対してFMISO-PET/CTを行い、検討を加えた。FMISOの高集積が見られた膵癌は再発しやすく、また早期に死亡する傾向が得られた。FMISO-PET/CTは、治療方針の決定など、膵癌のマネージメントにおいて重要な判断ができる可能性が示唆された。